TY - JOUR T1 - QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - 182 AU - Joachim H. Ficker AU - Jadwiga A. Wedzicha AU - Marc Decramer AU - Angel FowlerTaylor AU - Peter D'Andrea AU - Christie Arrasate AU - Hungta Chen AU - Donald Banerji Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/182.abstract N2 - IntroductionQVA149 is a once-daily (OD) dual bronchodilator combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (GLY) in development for the treatment of COPD. Here we present the results of a subgroup analysis from the SPARK study for the annualized rate of COPD exacerbations.MethodsThis 64 week, double-blind, parallel-group, active-controlled (open-label tiotropium [TIO]) study randomized patients ≥40 yrs with severe-to-very severe COPD to receive OD QVA149 110/50µg, GLY 50µg or TIO 18µg. Subgroups were based on age, gender, race, smoking status, COPD severity, inhaled corticosteroids (ICS) use and body mass index (BMI).Results2224 patients were randomized, 99.1% analyzed (QVA149=729, GLY=739, TIO=737); male: 74.8%, mean age: 63.3 years. For most subgroups, QVA149 significantly reduced the rate of COPD exacerbations versus GLY and TIO. Summary of exacerbation rates over 64 weeks is shown in table.View this table:Table: Rate ratio of all COPD exacerbations by subgroupsConclusionQVA149 110/50µg OD showed greater efficacy in reducing the rate of COPD exacerbations versus glycopyrronium and tiotropium for most subgroups. This provides evidence for the role of QVA149 in reducing exacerbations in severe-to-very severe COPD patients. ER -